RECEIVED CENTRAL FAX CENTER

JUN 0 6 2007

In re United States Patent Application of:

Docket No.:

4258-120

Applicants:

MASCARENHAS SARAIVA,

Examiner:

S. Kumar

Application No.:

10/574,875

Maria Joao, et al.

Date Filed:

April 6, 2006

Title:

COMPOUNDS FOR THE

TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID

FIBRILS

Customer No.:

23448

<u>Via facsimile To Examiner S. Kumar</u> (571) 273-0640

PROPOSED AMENDMENT OF CLAIMS

Please cancel claims 7-9, and amend claims 2-6, in the following listing of claims 1-9 of the application:

1. (Original) A compound of structural formula (I):

$$\begin{array}{c|c} F & O \\ \hline & C - R_1 \\ \hline & O - R_2 \\ \end{array}$$

(I)

in which

 R_1 is a -NR₃R_b group, where R_a and R_b , independently, are a hydrogen atom or a C_1 - C_6 alkyl group; -OR_C group, where R_C is a hydrogen atom or a C_1 - C_6 alkyl group; a glycosyl; a C_1 - C_6 polyhydroxyalkyl; or a -NH-CH(R_d)-COOR_e group, where R_d is a

side chain of one of the 20 natural alpha-amino acids in either of their two enantiomerically pure forms L or D, and R_e is a hydrogen atom or a C₁-C₆ alkyl group; and

 R_2 is a hydrogen atom, a C_1 - C_6 alkyl group, a glycosyl; a C_1 - C_6 polyhydroxyalkyl; -C(=O)- R_f group, where R_f is a C_1 - C_6 alkyl group; or a - CH_2 -COO- R_g group, where R_g is a hydrogen atom or a C_1 - C_6 alkyl group;

and pharmaceutically acceptable salts thereof.

- 2. (Currently amended) A compound according to claim 1, eharacterised in that wherein R_1 is selected from: OH, NH₂, OMe, OEt, or a CH(R_d)-COR_e group, where R_d is the side chain of glycine, alanine, leucine, valine, aspartic acid or asparagine and where R_e is H or a C_1 - C_6 alkyl group; and R_2 is selected from: H, Me, glycosyl, a -C(=O)- R_f group, where R_f is a Me, Et, t-Bu group; or a -CH₂-COO- R_g group, where R_g is a hydrogen atom or a t-Bu group.
- 3. (Currently amended) A compound according to claim 1, characterised in that it is selected from the following compounds group consisting of:
- [1] 5-(2,4-difluorophenyl)-3-iodo-salicylic acid;
- [2] ethyl 5-(2,4-difluorophenyl)-3-iodo-salicylate;
- [3] methyl 5-(2,4-difluorophenyl)-3-iodo-salicylate;
- [4] 5-(2,4-difluorophenyl)-3-iodo-salicylamide:
- [5] tert-butyl [2-aminocarbonyl-4-(2,4-difluorophenyl)-6-iodo-phenoxy]-acetale;
- [6] [2-aminocarbonyl-4-(2,4-difluorophenyl)-6-iodo-phenoxy]acetic acid;
- [7] 5-(2,4-difluorophenyl)-3-iodo-salicylic acid 1-O-β-glycoside;
- [8] ethyl 2',4'-difluoro-4-methoxy-5-iodo-[1,1']biphenyl-3-carboxylate;
- [9] 2',4'-difluoro-4-methoxy-5-iodo-[1,1']biphenyl-3-carboxylic acid;
- [10] ethyl 2',4'-difluoro-4-acetyloxy-5-iodo-[1,1']biphenyl-3-carboxylate;
- [11] 2',4'-difluoro-4-(t-butylcarbonyloxy)-5-iodo-[1,1']biphenyl-3-carboxylic acid;
- [12] 2',4'-difluoro-4-(ethylcarbonyloxy)-5-iodo-[1,1']biphenyl-3-carboxylic acid;
- [13] ethyl ester of N-[5-(2,4-difluorophenyl)-3-iodo-salicyloyl]glycine;
- [14] N-[5-(2,4-difluorophenyl)-3-iodo-salicyloyl]glycine;
- [15] N-[5-(2,4-difluorophenyl)-3-iodo-salicyloyl]alanine;
- [16] N-[5-(2,4-difluorophenyl)-3-iodo-salicyloyl]leucine;
- [17] N-[5-(2,4-difluorophenyl)-3-iodo-salicyloyl]serine;